Source:http://linkedlifedata.com/resource/pubmed/id/16033834
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
14
|
| pubmed:dateCreated |
2005-7-21
|
| pubmed:abstractText |
A receptor tyrosine kinase for ephrin ligands, EphB2 is expressed in colorectal cancer and has been proposed as a target for immunoconjugate therapy. The aim of this study was to perform a detailed histologic analysis of EphB2 expression in normal and neoplastic colorectal tissues. In addition, we sought to evaluate EphB2 expression as a prognostic factor in colorectal cancer. Expression of EphB2 was examined in normal colon (n = 28), colorectal cell lines (n = 20), colorectal adenomas (n = 148), primary cancers (n = 28), and metastases (n = 39) using immunohistochemistry. In addition, a series of primary cancers and matched normal (n = 342) with outcome data were profiled in tissue microarrays. The intensity of EphB2 expression was assessed in the entire series by immunohistochemistry, and in a subset by in situ hybridization. Overall survival and recurrence-free survival were correlated with EphB2 protein expression in retrospective subset analyses. Epithelial EphB2 expression was shown at all stages of colorectal tumorigenesis, including the base of all normal crypts, 77% of adenomas, 82% of primary cancers, and 64% of metastases. Although homogeneous expression was observed in adenomas, the pattern of staining was focal (mean 25%) in most malignant lesions. Patients whose tumor stained 2+ for EphB2 expression (versus 0/1+) exhibited significantly prolonged overall survival: mean duration of survival, 2,514 versus 1,044 days; hazard ratio, 0.45; 95% confidence interval, 0.18 to 0.95 (P = 0.035). In summary, EphB2 is expressed in normal crypts, colorectal adenomas, primary cancers, and metastases. High levels of EphB2 expression are associated with a longer mean duration of survival in colorectal cancer.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
1078-0432
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
11
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
5181-7
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading |
pubmed-meshheading:16033834-Adenoma,
pubmed-meshheading:16033834-Adult,
pubmed-meshheading:16033834-Aged,
pubmed-meshheading:16033834-Aged, 80 and over,
pubmed-meshheading:16033834-Animals,
pubmed-meshheading:16033834-Colorectal Neoplasms,
pubmed-meshheading:16033834-Disease-Free Survival,
pubmed-meshheading:16033834-Female,
pubmed-meshheading:16033834-Gene Expression Profiling,
pubmed-meshheading:16033834-Humans,
pubmed-meshheading:16033834-Immunohistochemistry,
pubmed-meshheading:16033834-Male,
pubmed-meshheading:16033834-Mice,
pubmed-meshheading:16033834-Middle Aged,
pubmed-meshheading:16033834-Neoplasm Metastasis,
pubmed-meshheading:16033834-Neoplasm Staging,
pubmed-meshheading:16033834-Prognosis,
pubmed-meshheading:16033834-Receptor, EphB2,
pubmed-meshheading:16033834-Tumor Cells, Cultured
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
EphB2 is a prognostic factor in colorectal cancer.
|
| pubmed:affiliation |
Department of Pathology, Genentech, Inc., South San Francisco, California 94080, USA. adrianjubb@gmail.com
|
| pubmed:publicationType |
Journal Article
|